Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good suggestion for corp. You and I had that experience that you related a few years ago.
Hi corp,
Since you own many shares I would encourage you to attend the ASM. You can't say that you listen to everything unless you do attend. After the initial presentation the mic goes off for the broadcasted part of the meeting and the meeting is over for the people listening online.
The floor then opens to the shareholders who attend and they can ask any board member or management member any questions. I think every board member except one was there and every top management member was there and many middle management members.
You don't just sit there and look them in the eyes.
You interact! Talk to them, ask questions, see how they react to your questions.
How much do you know about the board members other than reading their Bio's?
How much do you know about Dan Hart, Drew Brennan, Nick Furguson other than their Bio's on the webpage. I talked to Nick Furguson head of IT. This guy knows what he is doing and what a motivated guy. I think everyone can tell by the excellent quality of Avids webpage. My conversation with Nick Green was invaluable in my decision to continue my investment and add more at these lower prices.
IMO, If you would attend a ASM I think it would give you a whole new understanding of the company, the people at the company, what motivates them and the company culture. Things you can't get reading listening to what available online.
corporalagarn, thanks for sharing.
HGEN: Looks like that high volume selling at the end of the
day was because of a rebalancing. A whole bunch of stocks tanked starting at 3:50pm EST. HGEN went from 1.1 million volume to 3 million volume in 10 minutes with 895,277 shares being sold right at 4:00pm EST.
A couple hundred thousand shares trade in the last few minutes again today and almost everyday in the last few months.
Can anyone explain how this happens?
Are the shares really traded all day and then go through as one large block at the end of the day?
Good deduction. lol
https://ir.avidbio.com/news-releases/news-release-details/avid-bioservices-announces-expansion-viral-vector-development
Oct 24 2021 seven months ago
"The new facility’s analytical and process development laboratories are expected to come online more rapidly, with the potential to be operational within six-to-eight months."
4OurRetirement, yes I added one phrase 3min after the initial post with the 12,96$ remark.
eb0783, probably because part of it would be opened before the main production part was going to be opened.
Actually a smart move to start the preparatory work early so that if the facility is read and you can immediately start doing all the production line stuff and FDA line approvals.
AIMO
It looks like 11 of them are specific to the new viral vector facility. We are ramping up.
30 jobs listed up from 18 a couple of weeks ago.
https://avidbio.applicantpro.com/jobs/
Approaching New HighOfDay! Happy/Safe Memorial Weekend. glta,eom.
Let's Close OVER $14.00 And Trigger BreakOut AfterHours...
Giving More Reason To Celebrate This Memorial Weekend!
Anyone Up For Grilled Bear "Short"Ribs
Glta $CDMO Bulls, Watchers, & StockHOLDERS!
Be Safe & Have A Relaxing 3 Day Weekend...
Institutional Shares (Long) 74,761,137=121.08% (ex13D/G) glta.eom.
Up & Over $14! glta,eom.
EndoTarget, well your broker isn't in a hurry when he triggers a margin call :)
I only had one in my live, by a mistake on my behalf, and I had 48H to solve it myself before the Prime Broker would solve it with the Executive Broker and just sell whatever they saw fit.
And I think that 48H was a lot of leeway thanks to an otherwise perfect account situation.
By the way: We needed to break through 12,96$ to start the beginning of elasticity :)
AIMO
Hoping You Got More Then $13.49/Share! Glta,eom.
Let's Jump OVER $14.00 And Land Running! glta,eom.
MM are cautious.
Raising cent by cent and with really low volume avoiding too brutal spike but just wait for the elastic effect... It's gonna be spectacular.
IF the S&P breaks 3810 all bets are off ....I doubt that will happen !!
So, for CDMO,13.00 is a great entry point for all longs...technically I see us approaching
22.00 before a corrective pull-back....the next CC should give us answers regarding the plant build-out as well as future contract projections....GLTA...
Will raise my ASK to 23
Short interest dropped 450K
CDMO Short Interest
SETTLEMENT DATE SHORT INTEREST AVG. DAILY SHARE VOLUME DAYS TO COVER
05/13/2022 5,690,114 902,350 6.305884
04/29/2022 6,140,786 598,982 10.252038
04/14/2022 5,372,582 537,012 10.004585
03/31/2022 5,187,666 536,756 9.66485
03/15/2022 5,459,629 590,291 9.249047
02/28/2022 5,825,799 526,026 11.075116
02/15/2022 6,025,704 582,399 10.34635
01/31/2022 5,902,381 698,778 8.446718
01/14/2022 5,487,777 624,520 8.787192
12/31/2021 5,858,206 718,834 8.149595
EndoTarget, in such occasions just put them their with the AON flag set (all or nothing) and if you are aligned with the current PPS they will be gone quickly).
AIMO
Oops the message is from yesterday noon already. We closed at 12,75$ so I figure your problem is solved.
Not filled...
Too bad!
Let's try tomorrow @19
I need a buyer for 91,000@13.49 need to cover margin call.
Anyone?
Put some at 14.47
No one interested...
Recent DownGAP Still Needs Filled: $19.50~$19.40 From Apr-06-2022…
Glta $CDMO Bulls, Watchers, & StockHOLDERS
link:
http://www.stockta.com/cgi-bin/analysis.pl?symb=CDMO&cobrand=&mode=stock
Has anyone noticed that the short only has gone down the last two days from 10 to 9 yesterday and now it is 8.
Seems that some shorts are covering.
Yes, disregard. My mistake. That's what I get for doing something before coffee.
djohn, don't confuse the cat.
Knowing the whereabouts of shares is not the same as owning them all myself!
I don't smoke (at all) :)
AIMO
ASH is an oncology related convention. ASM is a shareholder meeting. Do you really want to compare attendance at those meetings or does ASH represent a typo I should disregard?
I agree that there is little retail ownership here, but I would say it's in the 3%-5% range, 2-3m shares.
I don't see attendance at the ASM as a good barometer. If you're right on retail ownership then I own about 20% of total retail shares. I have never attended an ASM and never really considered going. I read and listen into everything that I believe matters. I never felt the need to look into the eyes of management as I don't believe it would help me personally on my investment. Touring the facility would be nice I guess but I'm certainly not qualified to know what I'm looking at.
The exact amount of retails shares doesn't really matter, but it is certainly low.
So, you're telling me an individual with $2 million invested in a small cap company wouldn't attend that company's ASM?
What are you smoking?
Face it, there is little retail interest in Avid and no evidence there is.
djohn, I don't think ASM attendance of CDMO now can be compared with attendance when still PPHM. Other type of business. I have never attended a CDMO ASM, yet I still have my shares. But OK, that is only a single example.
probably COVID will also have played a role, not sure.
I wouldn't be surprised that on this board, all together, we have at least 3%. I know the whereabouts of near 1%. And I know that there are a few 100K+ position posting here on this board.
AIMO
thanks, guys. Interesting stories. As to shorting, any margin acct held shares can be lent by broker (fine print) -- and shorts carry voting privilege, too. (But shorter has to pay you the dividend due).
I would have been there with you in 2021 but there was still too much covid around and self-focused anti-maskers/anti-vaxers for me to want to fly yet.
I have attended the last 5 ASM and retail attendance has decreased as II ownership has increased. EB remember the enormous retail turn out at the 2019 ASH You, Me and one other couple. 2021 top that at 1. Just Me.
Stephanie, being the liaison between retail investors and Avid management/BOD received zero questions in advance from retail investors for management or the BOD at the 2021 ASH. If I remember she said that was very odd compared to prior years. Attendance at ASM, no retail investors engaging, the low number is people on this board and percent owned by II's, certainly points to very low retail investment in Avid.
But that's my opinion
Looks like AIM bought over 170K this morning. II now 120.46% up from 120.20% yesterday.
2022-05-24 NP AIM VARIABLE INSURANCE FUNDS (INVESCO VARIABLE INSURANCE FUNDS) - Invesco Oppenheimer V.I. Main Street Small Cap Fund Series II 341,070 53.84 6,948 7.39
jbainseky, I cant answer for "those so enamored with %II" but I can answer for myself as one of them.
The II% did NOT remain the same. It was in constant evolution since 18 Months. II trading with II? So some IIs take a loss to give other IIs an entry? I don't think so, well not massively anyway. If that would be the case we would see it in the list of IIs, it would continuously dramatically change. And it doesn't. It changes at it always did. A little in a little out.
And why would NEW IIs get in anyway if there was a fundamental problem with CDMO. Oh, yes, because Nick is going to sell us out, right!
AIMO
djohn, certainly not.
I know the whereabouts of about 1% of shares in retailers hands. And that is just me without all of you on this board and without employees, etc.
If Nick counts for a share count in case he received an acquisition offer then whatever game is played falls as a card house even BEFORE he decides to bring the offer to shareholders or not. because all shorts will have to be reversed.
So it will all depend on whether Nick wants to be taken over at a law price or not, but ONE SINGLE SIGNED letter to Nick, by one share holder, attracting his attention on the problem would FORCE him to do so. If not he becomes liable.
AIMO
EndoTarget, and NO company will take over MORE then the issued outstanding shares.
So if we have (say) 60Milj issued outstanding shares and there are 72 to 80Milj share in rotation due to short selling and 'lending on lending', then when Nick bring an acquisition offer he CANNOT bring it for more then 60Milj shares when he devides the price by the number of shares.
So one can see the problem! An off, say 60Mil, would mean 1$ per share. However, to get that dollar EVERY lender must cancel the related lending contract. That means every shorter must close its position an BUY the shares. But below 1$ that will be impossible. So they will need to up the price for REAL shareholders to sell. hence the price will go UP above 1$. Then Nick cannot sell at 1$ a share when the price at market would be 1.5$. etc, etc, etc.
AIMO
I have a good chunk of my financial future wrapped up here so while I haven't flown to CA I read, investigate, research, connect and try to understand every aspect of this company, industry and their leaders that I can. You all help me so much, thank you. Also, a post like yours EB makes me feel far less crazy. Knowing there's at least two of us makes me realize I won't be lonely in my pup tent on the street one day. LOL
I peaked at over 100,000 shares (0.3% of CDMO at that time), all in a number of family accounts, but slowly peeled over 80% of that off last year between $17 and $26. CDMO is now my 2nd largest holding behind HGEN. ALL my companies except CDMO are now in the red…. So I’m not real happy but that goes with owning biotech, which is the large majority of mine. There are many times when you just sit and wait for a number of years
That being said, I can see that you are much more diversified than I am…..much wiser. I still invest like a 30 year old….not much diversity and going for home runs instead of singles. That probably is not good for an over-70 year old.
On the other hand, I try to attend the ASMs of my largest holdings to “look into their eyes,” watch body language, listen to sidebars, and often take tours of their facilities. I got to tour CDMO facilities (Myford) in 2015 (before Myford was certified), 2016, 2017, 2018, and 2019 (new PD lab). ). Also, I obviously listen to any webcast, look at every presentation, and read all the research on my companies that you and the others bring to the boards. Thank you ALL very much! That all keeps me very close to my investments. So, I get to feel comfortable with my long waits for profit. I know you do the same thing.
I agree.
1% would be only around 600,000 shares.
I'm with you 100% on there being a small percentage of ownership left in the hands of retail but 200-300k is not even remotely close to the number.
I'm sorry but IMO there is very little retail left in CDMO.
One percent would be pushing it.
There is NO WAY those guesses are remotely close to correct, I'm sorry...
Not posting my number but it makes me SURE they're wrong.
Look at the biotech indices YTD:
^IXIC
-24.54%
^NBI
-23.90%
^SPSIBI
-38.58%
THE BIOTECH ROUT HAS BEEN ACROSS THE BOARD AND DEVASTATING TO MANY COMPANIES WHOM ARE DOING WELL AND PROSPERING WITH EARNINGS AND BACKLOGS, SO WHICH ARE NOW OVERSOLD AND GREAT PROSPECTS GOING FORWARD IMHO ... THIS GREAT LIL BURGEONING, GROWING CDMO WILL REBOUND UNLESS UNFORESEEN CIRCUMSTANCES, DERAIL THE GROWTH PROSPECTS ... THE CC WILL BRING GREAT REVELATION HOPEFULLY!
Volume looks interesting this morning.....someone wants shares and is bucking
the market to get them..............this is what building a bottom looks like !!
Could we get to 1,000,000 today? GLTA...
Why does to those so enamored with %II think institutions do not trade and that means illiquidity? Fund managers are always changing the composition of funds and what they own. A %II that remains fairly constant simply shows II are trading with II.
FFTT
JBAIN
Followers
|
836
|
Posters
|
|
Posts (Today)
|
4
|
Posts (Total)
|
346694
|
Created
|
11/07/03
|
Type
|
Free
|
Moderators Preciouslife1 4OurRetirement |
Avid Bioservices, Inc. (Nasdaq “CDMO”), Tustin CA. http://www.avidbio.com
President/CEO: Nicholas Green (eff. 7-30-20 https://tinyurl.com/yczapcc7 )
Four Avid Fact Sheets a/o 2-2020: https://avidbio.com/resources/fact-sheets/
Avid Bioservices is a CDMO committed to improving the lives of patients by manufacturing products derived from mammalian cell culture for the biotechnology & biopharmaceutical industries. Services include cGMP clinical & commercial product manufacturing, purification, bulk packaging, stability testing & regulatory strategy, submission, and support. The company also provides a variety of process development activities, including cell line development & optimization, cell culture & feed optimization, analytical methods development, and product characterization.
12-2019/Video: Tour of Myford Facility (2mins.): https://vimeo.com/380135562
7-2020: AVID’s Push Towards cv19 (I don’t capitalize things I hate) contracts: https://tinyurl.com/y8wzgneh
UPCOMING EVENTS: https://avidbio.com/events/
Sep1(Tue): Q1/FY21 (qe 7-31-20) Financials & Conf. Call - Transcript: https://tinyurl.com/y329llow
Sep17/Fireside Chat w/Nick Green: 18th Annual Morgan Stanley Global Healthcare Conf.: https://tinyurl.com/y4cbjjrc
Sep21-24/Virtual: Biotech Week Conf., Boston
Sep21-24/Virtual: BioProcess Intl. US Wes Conf., Santa Clara CA
...Time TBD: Presentation by Haiou Yang, PhD "Facility-Fit Driven Dev. for a mAb Production Process"
Oct20 10amPT/VIRTUAL: Annual Shareholders Mtg. https://tinyurl.com/y28blkjn 14A Proxy: https://tinyurl.com/y46ga9el
...ASM Replay (9:45): https://www.virtualshareholdermeeting.com/CDMO2020 (Control# not needed)
Apr20-22 2021/Booth#1159: INTERPHEX, NYC
Dec2(Wed) after mkt: Q2/FY21 (qe 10-31-20) Financials & Conf. Call - Transcript: https://tinyurl.com/y66xk888
Dec14-17: Antibody Engineering & Therapeutics Conf., San Diego
Quotes: Yahoo: Yahoo.com/CDMO Nasdaq: http://www.nasdaq.com/symbol/cdmo RT: http://www.nasdaq.com/symbol/cdmo/real-time
• IR: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 sdiaz@vidasp.com, Tim Brons (Media) 415-675-7402 tbrons@vidasp.com
SEC:
Latest 10Q 10-31-20 iss. 12-2-20 https://tinyurl.com/y3ournzr (Cash 10-31-20=$35.7mm)
Latest 10K 4-30-20 iss. 6-30-20 https://tinyurl.com/yak25nco (Cash 4-30-20=$36.3mm)
Latest DEF14A/Proxy iss. 8-27-20 (re: 10-20-20 ASM): https://tinyurl.com/y46ga9el
ALL SEC filings for CDMO: https://tinyurl.com/yc4zjyzv
CDMO's Corp. Bylaws (a/o 11-14-14): http://tinyurl.com/y8hsppea
Poison Pill adopted 3-16-06 for 10yrs: http://tinyurl.com/yvypvh 44-pg SEC filing: http://tinyurl.com/5m57ut BUNGLER explains in plain language: http://tinyurl.com/mft4nd6
...3-17-16 Poison Pill extended until 3-16-2021 https://tinyurl.com/y74glo2n (Form8A Amendment #1)
...Poison Pill TERMINATED eff. 9-23-2019 https://tinyurl.com/y2mzx3xo
SHARES:
Shares O/S as of 11-23-20=56,726,334 - history since 4-2006: https://tinyurl.com/y66xk888 (at bottom)
...A/O 10-31-20: 3,451,000 stock options outstanding at a wgt.avg. exercise price of $6.41 (pg.16 10Q).
...MarketWatch.com for CDMO (shows Float): https://www.marketwatch.com/investing/stock/cdmo
1-12-18: S-3 Shelf Registration filed for up to $125mm https://tinyurl.com/y9qtewpw
...12-14-20: Avid raises ~$34M gross, selling 3,833,335@9.00/sh. (underwriter: RBC Capital) https://tinyurl.com/y92yr9g4
...2-20-18: Avid Raises ~$21.8M net, selling 10,294,445@$2.25 (underwriter: Wells Fargo) 8-K: https://tinyurl.com/ya3nenth 424B5: https://tinyurl.com/ycpshgxl
Total INST.+LARGE Holdings now 41,617,965 73.5% a/o 9-30-20 https://tinyurl.com/y652nxpr
13 LARGEST SHAREHOLDERS a/o 9-30-20:
1. Eastern Capital (Kenneth Dart): 4,300,992 7.6% (a/o 8-21-19 14A/Proxy: https://tinyurl.com/y9c972fa – orig. 13G filed 11-2015)
2. Tappan Street (Prasad Phatak): 4,285,000 7.6% (a/o 12-31-19 13G: https://tinyurl.com/wlcwnnv )
3. Blackrock Inc. (Larry Fink): 3,834,816 6.8% (-111,172 a/o 9-30-20 Nasdaq Inst.)
4. IsZo Capital Mgt. (Brian Sheehy): 3,459,888 6.1% (-88,144 a/o 9-30-20 Nasdaq Inst.)
5. Millennium Mgt. 2,678,984 4.7% (+633,918 a/o 9-30-20 Nasdaq Inst.)
6. Vanguard Group 2,659,738 4.7% (-19,553 q/e 9-30-20 Nasdaq Inst.)
7. Snyder Capital 2,302,621 4.1% (-2,258 a/o 9-30-20 Nasdaq Inst.)
8. Altravue Capital 1,973,349 3.5% (+39,534 a/o 9-30-20 Nasdaq Inst.)
9. Wellington Mgt. 1,503,162 2.7% (+236,947 a/o 9-30-20 Nasdaq Inst.)
10. Sargent Invest. Grp. 1,052,099 1.9% (-11,000 a/o 9-30-20 Nasdaq Inst.)
11. State Street 992,280 1.8% (-65,922 a/o 9-30-20 Nasdaq Inst.)
12. Portolan Capital 963,374 1.7% (+528,662 a/o 9-30-20 Nasdaq Inst.)
13. Silvercrest Asset Mgt. 878,805 1.6% (-16,746 a/o 9-30-20 Nasdaq Inst.)
Inst. Holdings (Nasdaq) - updated 45-days after each qtr-end: http://www.nasdaq.com/symbol/cdmo/institutional-holdings
INSIDER-Trans: https://tinyurl.com/ycpw4j9z (formerly PPHM thru 2017: http://tinyurl.com/ypkow8 )
Short Interest, updated twice a month: https://www.nasdaq.com/symbol/cdmo/short-interest
A-T-M (At-The-Market) Sales 3/2009 - 7/14/17 ($272,500,000gr./34,869,747sh=$7.81/sh): http://tinyurl.com/yagmu2on
PPHM shares were 1:7 Reverse Split eff. 7-10-17 (315mm/$.606=>45mm/$4.24) http://tinyurl.com/yymtzcm9
PPHM shares were 1:5 Reverse Split eff. 10-19-09 (~237mm/$.64=>~47.4mm/$3.20) http://tinyurl.com/ykuw588
Potential Value: 9-19-2017: Catalent acquires CDMO Cook Pharmica for $950M ($179Msales x 5.3; EV/EBITDA=17.3) http://tinyurl.com/yd46m8py
AVID TEAM: https://avidbio.com/leadership/ - Open Jobs: https://avidbio.applicantpro.com/jobs
7-30-20: Nicholas Green (ex-Therapure Biopharma) becomes President/CEO of Avid - 6-25-20 PR: https://tinyurl.com/yczapcc7
4-13-20: Avid Hires 2 Senior Directors of Bus. Dev: Jason C. Brady & Sylvia Hinds https://tinyurl.com/sq2679g
1-8-20: Avid Appoints Timothy Compton as Chief Commercial Officer (repl. Tracy Kinjerski) https://tinyurl.com/ydww58sn
7-26-19: Catherine Mackey, PhD (ex Pfizer VP) joins Avid's BOD, replacing Joel McComb https://tinyurl.com/y3xhqmvm
5-8-19: Richard (Rick) B. Hancock named Interim President/CEO; Roger Lias resigns https://tinyurl.com/y4pqdwyc
7-16-18: Daniel Hart (ex-ENO Holdings) joins Avid as CFO https://tinyurl.com/ychz45p2
7-16-18: Michael Faughnan (ex-Lonza/WuXi Biologics) joins Avid as Sr.Dir./BusDev/WestC https://tinyurl.com/yaozdggz (Left 5-2019)
5-29-18: Sandra C. Carbonneau (ex-Lonza) joins Avid as Dir./BusDev./EastCoast https://tinyurl.com/ybvrwn2l (left 12-2019)
5-8-18: Magnus Schroeder (ex-AGC Biologics) joins Avid as VP/Process Sciences https://tinyurl.com/y7tpswaw
2-23-18: CFO Paul Lytle voluntarily resigns eff. 5-24-18 (2-23-18 +90days), "CFO search underway" https://tinyurl.com/ybnjzbv6
9-11-17: Roger J. Lias (ex-Allergan) to become Avid’s CEO and join PPHM’s BOD eff. 9-25-17 https://tinyurl.com/yddufw4s (left 5-8-19)
11-29-17: Tracy L. Kinjerski joins Avid as VP/Bus.Operations https://tinyurl.com/yc4zenkc (Left 1-8-2020)
Profiles of all 7 BOD members: http://ir.avidbio.com/corporate-governance/board-of-directors
...Joseph Carleone/Chair, Nicholas Green(CEO), Richard Hancock, Gregory Sargen, Mark Bamforth, Patrick Walsh, Catherine Mackey
10-24-17: Peregrine Adds Patrick D. Walsh to BOD, "An Industry Veteran with 30+yrs Experience Leading Successful CDMO Org’s” http://tinyurl.com/y3jo2rv7
10-19-17: Peregrine Adds Mark R. Bamforth to BOD, "10yrs/Genzyme; 30yrs of biologics leadership experience, incl. founding 2 CDMOs" http://tinyurl.com/y6ydcaof
ANALYST COVERAGE: http://ir.avidbio.com/analyst-coverage
Also see: https://www.marketbeat.com/stocks/NASDAQ/CDMO/price-target
Janney Montgomery Scott - Paul Knight PT=$10
H.C. Wainwright & Co. - Joseph Pantginis PT=$9
Craig-Hallum Capital Group - Matt G. Hewitt PT=$10
First Analysis Securities - Joseph Munda PT=$7.50
Stephens Inc. - Jacob Johnson PT=11 (10=>11 9-2-20)
FINANCIALS & BUSINESS DEV.:
2-3-21: Avid to Mfg. CV19 Therapeutic Lenzilumab for Humanigen https://tinyurl.com/1hzzksxa
8-26-20: Mapp Biopharmaceutical signs w/Avid for ClinDev of Antiviral Antibody (MBP091) https://tinyurl.com/yxwvr949 BARDA #HHSO100201900018C($16.5M+Opt/$30M), see: https://tinyurl.com/yye8t5nx
8-20-20: Oragenics signs Dev/Mfg Agreement with Avid for COVID-19 Vaccine “TerraCoV2” https://tinyurl.com/yxqg3w4v
8-6-20: Iovance Biotherapeutics signs w/Avid(+Aragen) to Dev+Mfg. IOV-3001 (IL-2 Analog) https://tinyurl.com/y2lgzh6x
7-28-20: Avid Teams with Argonaut to add “Parenteral Fill-Finish Services” https://tinyurl.com/y2lgzh6x
5-6-20: Avid Teams with Aragen to speed up drug dev./delivery timelines https://tinyurl.com/ycuu2m5r
4-23-20: Avid receives $4.4M PPP/CV19 Loan (can apply for forgiveness) 8K: https://tinyurl.com/yaltupxa
...5-12-20: Avid Pays Back $4.4M PPP/CV19 Loan (“New SBA Guidance/abundance of caution”) 8K: https://tinyurl.com/y993tkk6
3-10-20: CDMO's Revs & Burns By Qtr Table, FY07/Q1 thru FY20/Q3 (q/e 1-31-20): https://tinyurl.com/s9cmzmf
......Avid FY20 (fye 4-30-20) revenues guidance: $55-59M; committed backlog=$58mm at 1-31-2020.
7-8-19: Avid Signs New Top10 Global Pharma and Expands Existing Cust. Relationship https://tinyurl.com/yyq8zgb9
6-27-19: "The 5 new clients signed in late FY2018 contributed significantly to revenue diversification in FY2019." SEE CUST SPLITS for FY19: http://tinyurl.com/y5j4dlsv
4-24-18: ”In recent weeks, Avid has signed new agreements with 3 addl. undisclosed intl. drug dev. companies (that’s 4 thus far in CY2018)” https://tinyurl.com/y89whc8d
3-1-18: Acumen Pharm. selects Avid for Process Dev. & Mfg. of ACU193 (Alzheimer’s) https://tinyurl.com/y8jvwleq http://www.acumenpharm.com
2-21-18: Enzyvant selects Avid to commercially mfg. RVT-801 (Farber disease) https://tinyurl.com/yd5xhcx8 http://www.enzyvant.com
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...NOTE: 2-13-18: Oncologie Licenses Mologen’s immunotherapeutic ‘lefitolimod’ (TLR9 agonist) https://tinyurl.com/y9z54f4x “ONCOLOGIE is backed by top-tier intl. investors and has the objective to dev. novel personalized medicines in the field of immuno-oncology."
2-28-17: Avid & Cook (acq. by Catalent 12-2017 for $950M; $179Msales x 5.3; EV/EBITDA=17.3) remain Halozyme's 2 CMO's (“working to scale-up/validate/qualify Avid II/Myford for Roche collab.”): http://tinyurl.com/h75teta
FACILITIES: https://avidbio.com/facilities/
10-8-19: Avid Announces Completion of Expansion of Process Dev. Capabilities & Labs https://tinyurl.com/y3hfwst9
...will “significantly accelerate Avid’s ability to drive efficient & rapid on-boarding of new cust. pgms progressing to mfg.”
4-24-18: Avid adding Process Dev. Labs, upgrading capabilities (in phases; total will be >6000sq; 1st one ready Q3CY18/Jul-Sep'18) https://tinyurl.com/y89whc8d
5-2017: Avid II (Myford) adds 2 MilliporeSigma Mobius 2,000L single-use bioreactors; total mfg. capacity now ">11,000L". http://tinyurl.com/ky7bmu4
5-10-17: Halozyme comments on Avid II(Myford) expansion in their 3-31-17/10Q pub. 5-9-17: http://tinyurl.com/mrl34uk
..."validation of the new facility is scheduled to end in Q2/2017… Once this new facility is approved, it will become the primary source for Roche of bulk rHuPH20.”
6-2-16: Corp.Update – Avid Expansion & Drug Development - http://tinyurl.com/zvmhqmr
3-7-16/Avid II: Formal Commissioning of Avid's New 40,000sq "Myford" Facility, “single-use/fully disposable” (potentially $40M addl revs) http://tinyurl.com/y5jmfpo3
12-10-15/Avid II: Avid Expansion into MYFORD Facility now GMP-run ready (potential +$40mm sales) - contemplating further expansion http://tinyurl.com/y539yut4
12-10-14: Avid to Double Mfg. Capacity(“Myford Expansion”) http://tinyurl.com/y2sqoy2u & http://tinyurl.com/kmdgq8t
PRESENTATIONS & ARTICLES: https://avidbio.com/events/
Sep17/Fireside Chat w/Nick Green: 18th Annual Morgan Stanley Global Healthcare Conf.: https://tinyurl.com/y4cbjjrc
5-18-20: Avid Listed In Top CMO Awards Article https://tinyurl.com/yb5cnh6m
...”Avid received 5 CMO Leadership Awards categories, incl. 2 Champion designations: Expertise & Service.”
10-25-18/BioPharma: Roger Lias Interview, “Avid expansion to Triple Process Dev. Capacity” https://tinyurl.com/ybtuk29m
Sept2018/BioTechWEEK: Tracy Kinjerski (VP/BusOP) interview: Avid’s differentiators (6mins.) https://www.youtube.com/watch?v=x3tzo4pZivk
1-29-18: NobleCon14 - 14th Annual Inv. Conf., Ft.Laud. => Roger Lias' webcast/slideshow https://tinyurl.com/yanwk9yo
11-15-17/Outsourcing-Pharma: “How This R&D Company (Peregrine) is Transitioning to a Pure-Play CDMO: ‘Opportunities Are Almost Endless’" - Recap of interviews with Steve King & Avid Pres. Roger Lias http://tinyurl.com/y7dv9faz
CONFERENCE CALLS & ASM's:
12-2-20: Qtly. Conf. Call (Green/Hart/Compton) PR & Transcript https://tinyurl.com/y66xk888
10-20-20 Annual Shareholders Meeting - Replay (9:45): https://www.virtualshareholdermeeting.com/CDMO2020 (Control# not needed)
9-1-20: Qtly. Conf. Call (Green/Hart/Compton) PR & Transcript https://tinyurl.com/y329llow
...CEO N.Green: ”My first few weeks have done nothing but confirm my view that I believe Avid to be a strong and state-of-the-art company with significant opportunity for growth."
6-30-20: Qtly. Conf. Call (Hancock/Hart/Compton) PR & Transcript https://tinyurl.com/y9zbgmos
...RickH: "Based on our customers' growing demand and our expanding business development activity, we believe that we will significantly increase capacity utilization in 2021 and beyond. Accordingly, we have entered into a new phase of planning for the expansion that will support our growing business in the years to come.”
...”Top10 Pharma customer added 7-2019 named in 10-K: GILEAD SCIENCES.”
3-10-20: Qtly. Conf. Call (Hancock/Hart/Compton) PR & Transcript https://tinyurl.com/s9cmzmf
12-9-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript https://tinyurl.com/tfewuzc
9-5-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript https://tinyurl.com/y6t8zfur
6-27-19: Qtly. Conf. Call (Hancock/Hart/Kinjerski) PR & Transcript https://tinyurl.com/y6zdjyu2
...Rick Hancock, "Most importantly, during Q4, the Company achieved positive income, generating cash from dev. & mfg. operations for the 1st time since the beginning of the CDMO transition (Jan'18)."
3-11-19: Qtly. Conf. Call (Lias/Hart) PR & Transcript http://tinyurl.com/yy6dvjvc
12-3-18: Qtly. Conf. Call (Lias/Hart//Kinjerski) PR & Transcript https://tinyurl.com/y9n374kp
10-4-18: ASM/2018 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Report https://tinyurl.com/yctfzhlb
9-10-18: Qtly. Conf. Call (Lias/Hart) PR & Transcript https://tinyurl.com/y8oc6hx8
...Roger Lias, "During the qtr, we advanced the projects of our existing active clients and continue to engage with numerous potential new customers."
7-16-18: Qtly. Conf. Call (Lias/Kinjerski) PR & Transcript https://tinyurl.com/yaozdggz
...Roger Lias, “In a short period, we’ve established a targeted business dev. operation that is actively providing visibility for Avid Bioservices within our fast growing but competitive marketplace.”
3-12-18: Qtly. Conf. Call (Lias/Kinjerski/Lytle) PR & Transcript https://tinyurl.com/yakdl4wj
...Roger Lias, ”I'm pleased to be able to report that in a very short period of time we've generated significant interest from both emerging & growth biopharmaceutical players and from pharmaceutical multinationals. I'm confident that the plan we're executing will drive a considerable increase in backlog and the opportunity to further enhance capacity utilization in the future.”
......From the 3-12-18 PR: “At present, we are in late-stage negotiations with several potential new customers and expect to announce the executed agreements before the end of the FY[4-30-18].”
1-18-18: ASM/2017 (@Myford Facility) - Roger Lias’ Slideshow & Attendee Reports https://tinyurl.com/yca6enbr 12-7-17 PROXY/14A: https://tinyurl.com/y7qprpg9
12-11-17: Qtly. Conf. Call (Lias/Lytle) Transcript https://tinyurl.com/ybycb2s6
...Roger Lias, "the company is undergoing a broad-scale transformation, the goals of which are to shift complete focus to the Avid Bioservices CDMO business and the complete divestiture of all of Peregrine's legacy R&D assets, which include bavituximab."
9-11-17: Qtly. Conf. Call (King/Lias/Lytle) Transcript http://tinyurl.com/y9y8qdac
...Steve King: “For this reason, we have concluded that in order to best position Peregrine’s R&D assets for successful development, they should be advanced by a partner with the appropriate expertise and ample resources to invest in the necessary clinical trials. To that end, we have been working diligently towards the transformation of the overall business to becoming a pure-play CDMO, while assessing the best strategic options for the R&D assets that would allow stockholders to directly see the future value from their continued developments. By partnering & eliminating future R&D expenditures, we believe we are best positioning Avid for future growth. Through reinvestment & expansion, we believe we will attract new customers and extend current contracts that will help position Avid as a leading U.S. CDMO. We are moving forward expeditiously with strategic discussions as we recognize the need to move quickly both from the R&D & CDMO standpoints. We hope to bring this process to completion over the coming months and will update you on our progress.”
7-14-17: Qtly. Conf. Call (King/Shan/Lytle) Transcript http://tinyurl.com/yb4wulvu
...Steve King: “We are seriously considering the possibility of separating our 2 distinct businesses, Avid and R&D/PS-Targeting.”
3-13-17: Qtly. Conf. Call (King/Shan/Worsley/Lytle) Transcript http://tinyurl.com/grhwjvy
...Steve King: “We believe the recent improvement of stock price is a growing recognition of the value of Avid, and having the full value of the Avid business reflected in our stock price is a top priority.”
12-12-16: Qtly. Conf. Call (King/Shan/Hutchins/Lytle) Transcript http://tinyurl.com/hhn4gga
...Steve King: “Our goal is to bring the overall company to profitability within the next 18mos. We believe just the value of Avid Bioservices is far greater than our current market cap and is only growing in value."
10-13-16 ASM/2016: ATTENDEE Reports & Link to CEO Steve King's 35min/45slide webcast: http://tinyurl.com/jx7ouay
Feb. 2018: Peregrine Pharmaceuticals completed its Mid’17-Early’18 Transition to a Pure-Play CDMO
(Contract Development & Manufacturing Organization), Avid Bioservices, Inc. - CEO: Roger Lias.
**FULL PPHM=>CDMO Transition History (Ronin/SWIM): https://tinyurl.com/ybqvzwhg
1-8-17: Peregrine chgs. name to “Avid Bioservices, Inc.”; new ticker: “CDMO” (+CDMOP) https://tinyurl.com/y8vhjow4
2-12-18: Peregrine’s Legacy PS-Targeting IP Sold to ONCOLOGIE INC. (Boston, CEO: Laura E. Benjamin) for $8M/upfront, $95M/milestones https://tinyurl.com/yam8gb3h
...12-13-18/8-K: Overview of Oncologie sale: https://tinyurl.com/yab9c6cr
NOTE: “PS-targeting Exosome tech. not included; back to UTSW", see: https://tinyurl.com/yakdl4wj
Click here for an ARCHIVE of the History of Peregrine’s Anti-PS/Bavituximab Platform - MOA, Trials, and Activity over the years, from early 2000’s thru 2017, prior to being Sold to ONCOLOGIE:
https://tinyurl.com/y8pq4rhc
Of Interest (post Oncologie Sale):
Oncologie's website: https://oncologie.com/true-home-v2/ NEWS: https://oncologie.com/newsroom/
4-20-18/AACR’18: MSKCC(LudwigCC) Tweets about 2 WolchokLAB/”PPHM” Anti-PS Posters https://tinyurl.com/ycgjhvqa
4-26-18: New Bavi+Keytruda/LIVER Ph2 IST Trial, Sponsor=UTSW, Collab=MERCK https://tinyurl.com/y7fd9vdb
6-7-18: Oncologie Obtains $16.5M Seed Funding Led by Pivotal bioVenture Partners China Fund https://tinyurl.com/ybrrbgg7
6-7-18/BioCentury: Laura Benjamin states, “Oncologie plans to begin a trial mid-summer '18 evaluating Bavi to treat HCC and a P-O-C trial in Gastric cancer in 1Q19/2Q19.” https://tinyurl.com/ycb8r7sm
12-3-18: During q/e 10-31-18, Avid sold remaining legacy R&D asset, r84(anti-VEGF), to Oncologie for $1.0M upfront. Avid is eligible to receive up to an addl. $21M in dev/reg./comm. milestones, and low to mid-single digit royalties on net sales upon commercialization of products utilizing r84 https://tinyurl.com/y9n374kp
11-4-19/PharmaBoardroom: Interview with Oncologie CEO Laura Benjamin discussing the 2 ongoing Bavi Trials w/Keytruda (USA UK Taiwan S.Korea) https://tinyurl.com/ydf6zhsv
...Dr. Benjamin, "We have high expectations of bavituximab and have obtained the global rights for this compound."
...Ongoing Trial #1 (N=80): Open Label, Bavi+Keytruda Adv. Gastric/GEJ Cancer https://clinicaltrials.gov/ct2/show/NCT04099641
......1-17-2020 ASCO/GI Poster: https://oncologie.com/wp-content/uploads/2020/01/2020-01-17-ASGO-GI-poster-final-draft.pdf
...Ongoing Trial #2 (N=34 UTSW): Open Label, Bavi+Keytruda Adv. Hepatocellular Carcinoma https://clinicaltrials.gov/ct2/show/NCT03519997
6-11-20/Fiercebiotech: Oncologie Reels In $80M To Push Clinical Pgms/Build Pipeline https://tinyurl.com/yany8f34 & https://tinyurl.com/y8p9artk
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |